Psoriatic arthritis is commonly encountered in psoriasis patients. Its presentation varies and has several subtypes. Psoriatic arthritis should be differentiated from other forms of arthritis. The clinician must differentiate between the other potential various arthropathies that may be seen in patients with psoriasis. After the diagnosis is made, treatment can be tailored to the individual and his or her co-morbidities. There are several therapeutic options, ranging from nonsteroidal anti-inflammatory drugs to biologic drugs. In order to provide optimal care for the patient, the clinician should become versed in various diagnostic and therapeutic modalities of psoriatic arthritis.
KaneD.StaffordL.BresnihanB.FitzGeraldO.. A prospective, clinical and radiological study of early psoriatic arthritis: An early synovitis clinic experience.Rheumatology (Oxford).2003; 42(12): 1460–1468.
3.
Queiro-SilvaR.Torre-AlonsoJ.C.Tinture-EgurenT.Lopez-LagunasI.. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis.Ann Rheum Dis.2003; 62(1): 68–70.
4.
OgdieA.SchwartzmanS.HusniM.E.. Recognizing and managing comorbidities in psoriatic arthritis.Curr Opin Rheumatol2015; 27(2): 118–126.
5.
FeldmanS.R.ZhaoY.ShiL.TranM.H.LuJ.. Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis.Arthritis Care Res (Hoboken).2014.
6.
Edson-HerediaE.ZhuB.GuoJ.Maeda-ChubachiT.LebwohlM.. Disease burden and quality of life in psoriasis patients with and without comorbid psoriatic arthritis: Results from national psoriasis foundation panel surveys.Cutis.2015; 95(3): 173–178.
7.
ZachanaeH.ZachanaeR.BlomqvistK.Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations.Data from the Nordic Quality of Life Study Acta Derm Venereol.2002; 82(2): 108–113.
8.
KennedyM.PapnejaA.ThavaneswaranA.ChandranV.GladmanD.D.. Prevalence and predictors of reduced work productivity in patients with psoriatic arthritis.Clin Exp Rheumatol.2014; 32(3): 342–348.
9.
KawalecP.MalmowskiK.P.. The indirect costs of psoriatic arthritis Systematic review and meta-analysis.Expert Rev Pharmacoecon Outcomes Res.2015; 15(1): 125–132.
10.
GelfandJ.M.GladmanD.D.MeaseP.J.Epidemiology of psoriatic arthritis in the population of the United States.J Am Acad Dermatol2005; 53(4): 573.
11.
ReichK.KrugerK.MossnerR.AugustinM.. Epidemiology and clinical pattern of psoriatic arthritis in germany: A prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis.Br J Dermatol.2009; 160(5): 1040–1047.
12.
CatanosoM.PipitoneN.SalvaraniC.. Epidemiology of psoriatic arthritis.Reumatismo.2012; 64(2): 66–70.
13.
ShbeebM.UramotoK.M.GibsonL.E.O'FallonW.M.GabrielS.E.. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota USA, 1982–1991.J Rheumatol.2000; 27(5): 1247–1250.
WilsonF.C.IcenM.CrowsonC.S.Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: A population-based study.Arthritis Rheum.2009; 61(2): 233–239.
18.
CohenM.R.RedaD.J.CleggD.O.. Baseline relationships between psoriasis and psoriatic arthritis: Analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on seronegative spondyloarthropathies.J Rheumatol.1999; 26(8): 1752–1756.
19.
HelliwellP.S.. Therapies for dactylitis in psoriatic arthritis. A systematic review.J Rheumatol.2006; 33(7): 1439–1441.
20.
PelusoR.IervolinoS.VitielloM.Extra-articular manifestations in psoriatic arthritis patients.Clin Rheumatol.2015; 34(4): 745–753.
21.
ArmstrongA.W.GelfandJ.M.BoehnckeW.H.ArmstrongE.J.. Cardiovascular comorbidities of psoriasis and psoriatic arthritis: A report from the GRAPPA 2012 annual meeting.J Rheumatol.2013; 40(8): 1434–1437.
22.
OgdieA.YuY.HaynesK.Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: A population-based cohort study.Ann Rheum Dis.2015; 74(2): 326–332.
23.
ArmstrongA.W.HarskampC.T.ArmstrongE.J.. Psoriasis and metabolic syndrome: A systematic review and meta-analysis of observational studies.J Am Acad Dermatol.2013; 68(4): 654–662.
24.
BhattacharyaT.NardoneB.RademakerA.Co-existence of psoriasis and melanoma in a large urban academic centre population: A cross-sectional retrospective study.J Eur Acad Dermatol Venereol.2015; Jan 27.
25.
KurdS.K.TroxelA.B.Crits-ChristophP.GelfandJ.M.. The risk of depression, anxiety, and suicidality in patients with psoriasis: A population-based cohort study.Arch Dermatol.2010; 146(8): 891–895.
26.
TasliyurtT.BilirY.SahinS.Erectile dysfunction in patients with psoriasis: Potential impact of the metabolic syndrome.Eur Rev Med Pharmacol Sci.2014; 18(4): 581–586.
27.
RyanC.SadlierM.De VolE.Genital psoriasis is associated with significant impairment in quality of life and sexual functioning.J Am Acad Dermatol.2015; Jun;72(6): 978–83.
KounlovitchM.Galarza-MaldonadoC.Ortiz-PradoE.. Diagnosis and classification of rheumatoid arthritis.J Autoimmun.2014: 48–49: 26–30.
30.
Taruc-UyR.L.LynchS.A.. Diagnosis and treatment of osteoarthritis.Prim Care.2013; 40(4): 821–36, vii.
31.
SelmiC.GershwinM.E.. Diagnosis and classification of reactive arthritis.Autoimmun Rev.2014; 13(4-5): 546–549.
32.
OlivieriI.CantiniF.SalvaraniC.. Diagnostic and classification criteria, clinical and functional assessment, and therapeutic advances for spondyloarthropathies.Curr Opin Rheumatol.1997; 9(4): 284–290.
BiagioniB.J.GladmanD.D.CookR.J.Reliability of radiographic scoring methods in axial psoriatic arthritis.Arthritis Care Res (Hoboken).2014; 66(9): 1417–1422.
35.
GoldR.H.BassettL.W.SeegerL.L.. The other arthntides. roentgenologic features of osteoarthritis, erosive osteoarthritis, ankylosing spondylitis, psoriatic arthritis, reiter's disease, multicentric reticulohistiocytosis, and progressive systemic sclerosis.Radiol Clin North Am.1988; 26(6): 1195–1212.
36.
HelliwellP.S.. Relationship of psoriatic arthritis with the other spondyloarthropathies.Curr Opin Rheumatol.2004; 16(4): 344–349.
37.
HelliwellP.S.HicklingP.WrightV.. Do the radiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease, psoriasis and reactive arthritis?Ann Rheum Dis.1998; 57(3): 135–140.
38.
Perez-RuizF.CastilloE.ChinchillaS.P.Herrero-BeitesA.M.. Clinical manifestations and diagnosis of gout.Rheum Dis Clin North Am.2014; 40(2): 193–206.
39.
KhondkerL.KhanS.I.. Association of rheumatoid factor and uric acid with psoriatic arthritis: A review.Mymensingh Med J.2014; 23(3): 609–613.
40.
BruceI.N.SchentagC.T.GladmanD.D.. Hyperuricemia in psoriatic arthritis: Prevalence and associated features.J Clin Rheumatol.2000; 6(1): 6–9.
41.
GisondiP.. Hyperuricemia in patients with chronic plaque psoriasis.Drug Dev Res.2014; 75: S70–S72.
42.
MerolaJ.F.WuS.HanJ.ChoiH.K.QureshiA.A.. Psoriasis, psoriatic arthritis and risk of gout in US men and women.Ann Rheum Dis.2015; Aug;74(8): 1495–500.
43.
SheaB.SwindenM.V.GhogomuE.T.Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.J Rheumatol.2014; 41(6): 1049–1060.
44.
WuS.ChoE.LiWQHanJ.QureshiA.A.. Alcohol intake and risk of incident psoriatic arthritis in women.J Rheumatol.2015; May; 42(5): 835–40.
45.
ZouL.Lonne-RahmS.B.HelanderA.Alcohol intake measured by phosphatidylethanol in blood and the lifetime drinking history interview are correlated with the extent of psoriasis.Dermatology.2015; 230(4): 375–80.
46.
ArmstrongA.W.HarskampC.T.DhillonJ.S.ArmstrongE.J.. Psoriasis and smoking: A systematic review and meta-analysis.Br J Dermatol.2014; 170(2): 304–314.
CassellS.E.BieberJ.D.RichP.The modified nail psoriasis severity index: Validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis.J Rheumatol.2007; 34(1): 123–129.
50.
OlivienI.ScaranoE.PadulaA.D'AngeloS.. Imaging of psoriatic arthritis.Reumatismo.2007; 59 Suppl 1: 73–76.
51.
SiannisF.FarewellV.T.CookR.J.SchentagC.T.GladmanD.D.. Clinical and radiological damage in psoriatic arthritis.Ann Rheum Dis.2006; 65(4): 478–481.
52.
WiellC.SzkudlarekM.HasselquistM.Ultrasonography, magnetic resonance imaging, radiography, and clinical assessment of inflammatory and destructive changes in fingers and toes of patients with psoriatic arthritis.Arthritis Res Ther.2007; 9(6): R119.
53.
Zlatkovic-SvendaM.Kerimovic-MorinaD.StojanovicR.M.. Psoriatic arthritis classification criteria: Moll and wright, ESSG and CASPAR – a comparative study.Acta Reumatol Port.2013; 38(3): 172–178.
54.
TaylorW.GladmanD.HelliwellP.Classification criteria for psoriatic arthritis: Development of new criteria from a large international study.Arthritis Rheum.2006; 54(8): 2665–2673.
55.
LinM.V.BlonskiW.BuchnerA.M.ReddyK.R.LichtensteinG.R.. The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease.Dig Dis Sci.2013; 58(4): 1149–1156.
56.
PompiliM.BiolatoM.MieleL.GriecoA.. Tumor necrosis factor-alpha inhibitors and chrome hepatitis C: A comprehensive literature review.World J Gastroenterol.2013; 19(44): 7867–7873.
57.
DohertyS.D.Van VoorheesA.LebwohlM.G.National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.J Am Acad Dermatol.2008; 59(2): 209–217.
58.
ChuangT.Y.HeinrichL.A.SchultzM.D.PUVA and skin cancer. A historical cohort study on 492 patients.J Am Acad Dermatol.1992; 26(2 Pt 1): 173–177.
59.
SternR.S.NicholsK.T.VakevaL.H.. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA), the PUVA follow-up study.N Engl J Med.1997; 336(15): 1041–1045.
60.
SorianoE.R.McHughN.J.. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review.J Rheumatol.2006; 33(7): 1422–1430.
61.
StorrsF.J.. Use and abuse of systemic corticosteroid therapy.J Am Acad Dermatol.1979; 1(2): 95–106.
SorianoE.R.. The actual role of therapy with traditional disease-modifying antirheumatic drugs in psoriatic arthritis.J Rheumatol Suppl.2012; 89: 67–70.
64.
PloskerG.L.CroomK.F.. Sulfasalazine: A review of its use in the management of rheumatoid arthritis.Drugs.2005; 65(13): 1825–1849.
65.
MellesR.B.MarmorM.F.. The risk of toxic retinopathy in patients on long-term hydroxychloroguine therapy.JAMA Ophthalmol.2014; 132(12): 1453–1460.
66.
MarmorM.F.KellnerU.LaiT.Y.LyonsJ.S.MielerW.F., American Academy of Ophthalmology. Revised recommendations on screening for chloroguine and hydroxychloroguine retinopathy.Ophthalmology.2011; 118(2): 415–422.
WolfR.RuoccoV.. Triggered psoriasis.Adv Exp Med Biol.1999; 455: 221–225.
69.
MeaseP.. Methotrexate in psoriatic arthritis.Bull Hosp Jt Dis (2013).2013; 71 Suppl 1: S41–5.
70.
ChiaravallotiA.J.StroberB.E.. The use of self-administered subcutaneous methotrexate for the treatment of psoriasis.J Drugs Dermatol.2014; 13(8): 929–931.
71.
PichlmeierU.HeuerK.U.. Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate.Clin Exp Rheumatol.2014; 32(4): 563–571.
72.
LynchM.HigginsE.McCormickP.A.The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.JAMA Dermatol.2014; 150(8): 856–862.
73.
KalbR.E.StroberB.WeinsteinG.LebwohlM.. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference.J Am Acad Dermatol.2009; 60(5): 824–837.
74.
MayburyC.M.SamarasekeraE.DouinA.BarkerJ.N.SmithC.H.. Diagnostic accuracy of noninvasive markers of liver fibrosis in patients with psoriasis taking methotrexate: A systematic review and meta-analysis.Br J Dermatol.2014; 170(6): 1237–1247.
75.
GisondiP.GalvanA.IdolazziL.GirolomoniG.. Management of moderate to severe psoriasis in patients with metabolic comorbidities.Front Med (Lausanne).2015; 2: 1.
76.
KavanaughA.MeaseP.J.Gomez-ReinoJ.J.Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.Ann Rheum Dis.2014; 73(6): 1020–1026.
77.
ItoT.FurukawaF.IwatsukiK.Efficacious treatment of psoriasis with low-dose and intermittent cyclosporin microemulsion therapy.J Dermatol.2014; 41(5): 377–381.
78.
D'SouzaL.S.PayetteM.J.. Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis.J Am Acad Dermatol.2015; 72(4): 589–598.
79.
MenterA.GottliebA.FeldmanS.R.Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.J Am Acad Dermatol.2008; 58(5): 826–850.
80.
LebwohlM.BagelJ.GelfandJ.M.From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis.J Am Acad Dermatol.2008; 58(1): 94–105.
81.
GelfandJ.M.BerlinJ.Van VoorheesA.MargolisD.J.. Lymphoma rates are low but increased in patients with psoriasis: Results from a population-based cohort study in the United Kingdom.Arch Dermatol.2003; 139(11): 1425–1429.
82.
PanserD.M.LeonardiC.L.GordonK.Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis.J Am Acad Dermatol.2012; 67(2): 245–256.
83.
SerorR.RichezC.SordetC.Pattern of demyelination occurring during anti-TNF-α therapy: A French national survey.Rheumatology (Oxford).2013; 52(5): 868–874.
84.
De SimoneC.AmenoP.AmorusoG.Immunogenicity of anti-TNF-α therapy in psoriasis: A clinical issue?Expert Opin Biol Ther.2013; 13(12): 1673–1682.
85.
TakeshitaJ.WangS.ShinD.B.Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting.J Am Acad Dermatol.2014; 71(6): 1167–1175.
86.
PappK.A.LangleyR.G.LebwohlM.Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, n patients with psoriasis: 52-week results from a randomised double-blind, placebo-controlled trial (PHOENIX 2).Lancet2008: 371(9625): 1675–1684.
87.
GirolomomG.MrowietzU.PaulC.. Psoriasis: Rationale for targeting interleukin-17.Br J Dermatol.2012; 167(4): 717–724.
